Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689697 | 0.92 | NAMPT (0.35) | P2RX7SCDSCD5NAMPTEGLN1 | |
| SCHEMBL3691190 | 0.92 | SCD (0.37) | SCDSCD5NAMPTTRPV1MAPT | |
| SCHEMBL3690381 | 0.91 | NAMPT (0.35) | SCDSCD5NAMPTEGLN1TRPV1 | |
| SCHEMBL3690179 | 0.90 | SCD (0.39) | SCDSCD5NAMPTTRPV1MAPT | |
| SCHEMBL13261355 | 0.90 | NAMPT (0.37) | P2RX7SCDSCD5NAMPTTRPV1 | |
| SCHEMBL3686611 | 0.89 | MAPT (0.40) | SCDSCD5NAMPTEGLN1TRPV1 | |
| SCHEMBL3688408 | 0.88 | NAMPT (0.33) | SCDSCD5NAMPTEGLN1TRPV1 | |
| SCHEMBL3689929 | 0.87 | ALDH1A1 (0.34) | SCDSCD5NAMPTEGLN1TRPV1 | |
| SCHEMBL3694143 | 0.87 | NAMPT (0.33) | SCDSCD5NAMPTEGLN1TRPV1 | |
| SCHEMBL3697505 | 0.87 | NAMPT (0.36) | SCDSCD5NAMPTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | P2RX7 589/4885SCD 1226/4885SCD5 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.